OpenURL Connection Search

Select item for more details and to access through your institution.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study.
Published in:
British Journal of Haematology, 2019, v. 186, n. 3, p. e35, doi. 10.1111/bjh.15879
By:
- Plesner, Torben;
- Arkenau, Hendrik‐Tobias;
- Gay, Francesca;
- Minnema, Monique C.;
- Boccadoro, Mario;
- Moreau, Philippe;
- Cavenagh, Jamie;
- Perrot, Aurore;
- Laubach, Jacob P.;
- Krejcik, Jakub;
- Ahmadi, Tahamtan;
- Boer, Carla;
- Chen, Diana;
- Chiu, Christopher;
- Schecter, Jordan M.;
- Richardson, Paul G.
Publication type:
Article
Daratumumab for the Treatment of Multiple Myeloma.
Published in:
Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.01228
By:
- Plesner, Torben;
- Krejcik, Jakub
Publication type:
Article
Harnessing the Immune System to Fight Multiple Myeloma.
Published in:
Cancers, 2021, v. 13, n. 18, p. 4546, doi. 10.3390/cancers13184546
By:
- Krejcik, Jakub;
- Barnkob, Mike Bogetofte;
- Nyvold, Charlotte Guldborg;
- Larsen, Thomas Stauffer;
- Barington, Torben;
- Abildgaard, Niels
Publication type:
Article
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Published in:
Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
By:
- Adams, Homer C.;
- Stevenaert, Frederik;
- Krejcik, Jakub;
- Van der Borght, Koen;
- Smets, Tina;
- Bald, Jaime;
- Abraham, Yann;
- Ceulemans, Hugo;
- Chiu, Christopher;
- Vanhoof, Greet;
- Usmani, Saad Z.;
- Plesner, Torben;
- Lonial, Sagar;
- Nijhof, Inger;
- Lokhorst, Henk M.;
- Mutis, Tuna;
- Donk, Niels W.C.J.;
- Sasser, Amy Kate;
- Casneuf, Tineke
Publication type:
Article

Found: 4

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study.

Daratumumab for the Treatment of Multiple Myeloma.

Harnessing the Immune System to Fight Multiple Myeloma.

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.